05 vs BUD. Overall, withdrawal rates were lower in studies I and IV than in studies II and III (figure 1). The percentage of patients with mild to selleck chemicals moderate asthma (study I) who withdrew due to ≥1 predefined asthma event was similar in the BUD/FM and BUD groups. Percentages of patients with moderate to severe asthma (studies II, III, and IV) who withdrew due to ≥1 asthma event were numerically lower in the BUD/FM versus BUD groups, regardless of race. Additional GSK690693 price results from the individual studies have been previously described.[5–8] Conclusions Predefined asthma events are increasingly being utilized in clinical research studies as a sensitive composite control metric. An asthma event metric encompassing
measures of pulmonary function, symptoms, rescue medication use, and the need for additional medications was investigated in the present analysis. While individual studies were not powered for statistical analyses, predefined asthma event rates in four 12-week, randomized studies consistently showed numerical or significant differences favoring BUD/FM pMDI over BUD across White, Black, and Hispanic patients, regardless of disease severity. Notably, the results of this analysis showing similar predefined asthma event rates among patients of differing racial backgrounds is consistent with the primary analyses showing the efficacy of BUD/FM
pMDI in Blacks and Hispanics, as well as a study demonstrating the efficacy of ICS/LABA in Blacks. Additional discussion of findings and buy Tozasertib limitations
of the individual studies have been previously discussed.[5–8] Differences between the BUD/FM pMDI and BUD groups were smaller in patients with mild to moderate asthma than in patients with moderate to severe asthma, most likely because patients with milder disease had overall lower asthma event rates. These Demeclocycline data further support the efficacy of BUD/FM pMDI in achieving asthma control in patients with moderate to severe asthma, regardless of race. Acknowledgements This study was supported by AstraZeneca LP, Wilmington, DE, USA. Medical writing services, provided by Lisa Feder, PhD (Scientific Connexions, Newtown, PA, USA), were funded by AstraZeneca LP. K.R. Murphy, T. Uryniak, U.J. Martin, and J. Zangrilli made substantial contributions to the analysis and interpretation of data, drafted and revised the manuscript critically for important intellectual content, and provided final approval of the version to be published. K.R. Murphy is a(n) consultant and advisor to and has received lecture fees and grants from AstraZeneca LP. T. Uryniak, U.J. Martin, and J. Zangrilli are shareholders and employees of AstraZeneca LP. References 1. American Lung Association. Trends in asthma morbidity and mortality. July 2011 [online]. Available from URL: http://www.lungusa.org/finding-cures/our-research/trend-reports/asthma-trend-report.pdf [Accessed 2011 Oct 21] 2.